NeuroSense Therapeutics (NRSN) Liabilities and Shareholders Equity (2020 - 2025)
NeuroSense Therapeutics' (NRSN) quarterly Liabilities and Shareholders Equity came in at $1.0 million in Q4 2025, down 77.53% year-over-year from $4.6 million in Q4 2024, and down 38.95% quarter-over-quarter from $1.7 million in Q2 2025.
Powered by 
Analysis
NeuroSense Therapeutics (NRSN) Liabilities and Shareholders Equity (2020 - 2025) Analysis & Trends
NeuroSense Therapeutics has disclosed Liabilities and Shareholders Equity across 6 years of filings, most recently posting $1.0 million for Q4 2025.
- In Q4 2025, Liabilities and Shareholders Equity fell 77.53% year-over-year to $1.0 million; the TTM figure through Dec 2025 stood at $8.3 million (down 6.5% YoY), while the FY2025 annual figure was $1.0 million, down 77.53% from the prior year.
- Liabilities and Shareholders Equity came in at $1.0 million for Q4 2025 at NeuroSense Therapeutics, down from $1.7 million in the prior quarter.
- In the past five years, Liabilities and Shareholders Equity ranged from a high of $14.4 million in Q1 2022 to a low of $984000.0 in Q3 2024.
- Average Liabilities and Shareholders Equity over 5 years is $5.8 million, with a median of $5.3 million recorded in 2023.
- Year-over-year, Liabilities and Shareholders Equity soared 1367.39% in 2021 and tumbled 81.73% in 2024.
- Over 5 years, Liabilities and Shareholders Equity stood at $11.4 million in 2021, then sank by 32.49% to $7.7 million in 2022, then tumbled by 58.73% to $3.2 million in 2023, then surged by 43.64% to $4.6 million in 2024, then slumped by 77.53% to $1.0 million in 2025.
- Per Business Quant data, the three most recent Liabilities and Shareholders Equity figures were $1.0 million in Q4 2025, $1.7 million in Q2 2025, and $4.6 million in Q4 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 208.48 Bn | 194.49 Bn | 7.24 Bn | 95.64 Bn |
| 2 | Gilead Sciences | 186.29 Bn | 183.02 Bn | 6.22 Bn | 49.36 Bn |
| 3 | Vertex Pharmaceuticals | 128.79 Bn | 120.93 Bn | 2.84 Bn | 27.42 Bn |
| 4 | Regeneron Pharmaceuticals | 80.66 Bn | 72.67 Bn | 3.93 Bn | 41.73 Bn |
| 5 | Moderna | 61.46 Bn | 56.32 Bn | 52.00 Mn | 10.96 Bn |
| 6 | Argenx Se | 61.28 Bn | 56.10 Bn | 1.37 Bn | 10.03 Bn |
| 7 | Alnylam Pharmaceuticals | 32.04 Bn | 28.73 Bn | 992.69 Mn | 5.56 Bn |
| 8 | Biogen | 31.84 Bn | 30.56 Bn | 1.96 Bn | 32.09 Bn |
| 9 | Roivant Sciences | 28.74 Bn | 29.43 Bn | 1.16 Mn | 5.31 Bn |
| 10 | NeuroSense Therapeutics | 8.09 Mn | 7.88 Mn | - | 1.03 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 1.03 Mn |
| Jun 30, 2025 | 1.68 Mn |
| Dec 31, 2024 | 4.58 Mn |
| Sep 30, 2024 | 984,000.00 |
| Jun 30, 2024 | 1.84 Mn |
| Mar 31, 2024 | 1.45 Mn |
| Dec 31, 2023 | 3.19 Mn |
| Sep 30, 2023 | 5.39 Mn |
| Jun 30, 2023 | 7.87 Mn |
| Mar 31, 2023 | 5.34 Mn |
| Dec 31, 2022 | 7.72 Mn |
| Sep 30, 2022 | 9.23 Mn |
| Jun 30, 2022 | 11.45 Mn |
| Mar 31, 2022 | 14.36 Mn |
| Dec 31, 2021 | 11.43 Mn |
| Dec 31, 2020 | 779,000.00 |
API Access
NeuroSense Therapeutics Liabilities and Shareholders Equity API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=liabilities-and-shareholders-equity&ticker=NRSN&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "liabilities-and-shareholders-equity", "ticker": "NRSN", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=liabilities-and-shareholders-equity&ticker=NRSN&period=max&api_key=YOUR_API_KEY");
const data = await res.json();